skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Informa pharma logo

ファーマインテリジェンスはInforma PLCのインフォーマインテリジェンス部門の一部です

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Pharma Intelligence Logo
Search Icon レポートストアおすすめコンテンツ製品ログインProductLogin
Global Search Configuration
  • Close Icon

About Joseph

Maryland, {6D506EDE-F0E4-4964-93FF-D8A3DA23BDA0}

+12 year(s) experience

Joe Haas
Joe has covered a wide range of biopharmaceutical stories for the past 11 years and contributes to Pink Sheet, Scrip and related Informa publications. His specialties include business development, commercial strategies and infectious diseases.
Joe began reporting on the pharmaceutical industry upon joining the Pink Sheet in 2007. Key developments he has analyzed include Genzyme’s acquisition by Sanofi; the dynamics of the hepatitis C market from the development of telaprevir and boceprevir through the market’s emergence into a mature therapeutic space; nascent R&D efforts in NASH; and deal-making among pharma, biotechs and academic/research institutions.

Specialties

  • Biopharma Pipeline Strategy
  • Biotech
  • Commercial Strategy

Joseph Writes For

Events Joseph is speaking at

31 Oct 2019 , 15:00

Webinar

Outlook for NASH Therapies and Market Dynamics

Presenters:
  • joseph-haas
Register

Analyst Articles

Articles by Joseph